PR-LncRNA signature regulates glioma cell activity through expression of SOX factors

Scientific Reports
Sergio Torres-BayonaAnder Matheu

Abstract

Long non-coding RNAs (LncRNAs) have emerged as a relevant class of genome regulators involved in a broad range of biological processes and with important roles in tumor initiation and malignant progression. We have previously identified a p53-regulated tumor suppressor signature of LncRNAs (PR-LncRNAs) in colorectal cancer. Our aim was to identify the expression and function of this signature in gliomas. We found that the expression of the four PR-LncRNAs tested was high in human low-grade glioma samples and diminished with increasing grade of disease, being the lowest in glioblastoma samples. Functional assays demonstrated that PR-LncRNA silencing increased glioma cell proliferation and oncosphere formation. Mechanistically, we found an inverse correlation between PR-LncRNA expression and SOX1, SOX2 and SOX9 stem cell factors in human glioma biopsies and in glioma cells in vitro. Moreover, knock-down of SOX activity abolished the effect of PR-LncRNA silencing in glioma cell activity. In conclusion, our results demonstrate that the expression and function of PR-LncRNAs are significantly altered in gliomagenesis and that their activity is mediated by SOX factors. These results may provide important insights into the mechanisms r...Continue Reading

References

Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Apr 20, 2010·Cancer Cell·Houtan NoushmehrUNKNOWN Cancer Genome Atlas Research Network
Sep 8, 2012·Nature·Sarah DjebaliThomas R Gingeras
Feb 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Akio IwanamiPaul S Mischel
Apr 24, 2013·Recent Patents on Anti-cancer Drug Discovery·Estefania Carrasco-GarciaAnder Matheu
Oct 15, 2013·Cell·Cameron W BrennanUNKNOWN TCGA Research Network
May 21, 2014·Neuro-oncology·Quinn T OstromJill S Barnholtz-Sloan
Nov 25, 2014·Stem Cell Reports·Usue EtxanizAnder Izeta
Aug 1, 2015·Cancers·Karrie Mei-Yee KiangGilberto Ka-Kit Leung
Nov 6, 2015·Nature Medicine·Maite Huarte
Feb 16, 2016·Expert Opinion on Therapeutic Targets·Laura Garros-RegulezAnder Matheu
Sep 21, 2016·Journal of Neuro-oncology·Akshitkumar M MistryRebecca A Ihrie
Nov 9, 2016·Frontiers in Oncology·Laura Garros-RegulezAnder Matheu
Dec 7, 2016·Nature Communications·Keisuke KatsushimaYutaka Kondo
Feb 12, 2017·Oncotarget·Jia ShiSuinuan Wang
Apr 21, 2017·Scientific Reports·Idoia GarciaAnder Matheu
May 10, 2017·The Lancet Oncology·Michael WellerUNKNOWN European Association for Neuro-Oncology (EANO) Task Force on Gliomas
Jul 8, 2017·Journal of Neuro-oncology·Al-Wala AwadMark A Mahan

❮ Previous
Next ❯

Citations

Jul 10, 2019·Cancers·Ander Saenz-AntoñanzasAnder Matheu
Sep 13, 2020·Journal of Cellular and Molecular Medicine·Wanghao ChenLukui Chen
Nov 1, 2020·Cells·Christian T StackhouseChristopher D Willey

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
PCR
antisense oligonucleotide
surgical resection
reverse transcription PCR

Software Mentioned

MathWorksTM
NIS Elements Advances Research
Matlab

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.